Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice

Heart failure (HF) is a complex syndrome that affects mortality/morbidity and acts at different levels in the patient's life, resulting in a drastic impairment in multiple aspects of daily activities (e.g. physical, mental/emotional, and social) and leading to a reduction in quality of life. The definition of disease status and symptom severity has been traditionally based on the physician assessment, while the patient's experience of disease has been long overlooked. The active participation of patients in their own care is necessary to better understand the perception of disease and the multiple aspects of life affected, and to improve adherence to treatments. Patient‐reported outcomes (PROs) aim to switch traditional care to a more patient‐centred approach. Although PROs demonstrated precision in the evaluation of disease status and have a good association with prognosis in several randomized controlled trials, their implementation into clinical practice is limited. This review discusses the modalities of use of PROs in HF, summarizes the most largely adopted PROs in HF care, and provides an overview on the application of PROs in trials and the potential for their transition to clinical practice. By discussing the advantages and the disadvantages of their use, the reasons limiting their application in daily clinical routine, and the strategies that may promote their implementation, this review aims to foster the systematic integration of the patient's standpoint in HF care.

[1]  E. Leifer,et al.  Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel. , 2022, JACC. Heart failure.

[2]  J. Spertus,et al.  Impact of Patient-Reported Outcome Measurement in Heart Failure Clinic on Clinician Health Status Assessment and Patient Experience: A Substudy of the PRO-HF Trial , 2022, Circulation. Heart failure.

[3]  Akshay S. Desai,et al.  Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.

[4]  L. Lund,et al.  Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry , 2022, European journal of heart failure.

[5]  P. Ponikowski,et al.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.

[6]  L. Lund,et al.  Global burden of heart failure: A comprehensive and updated review of epidemiology. , 2022, Cardiovascular research.

[7]  Sanjiv J. Shah,et al.  Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial , 2021, Circulation.

[8]  G. Fonarow,et al.  Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[9]  N. Samani,et al.  Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire , 2021, European journal of heart failure.

[10]  P. Ponikowski,et al.  Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial , 2021, European journal of heart failure.

[11]  P. Ponikowski,et al.  Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial , 2021, European heart journal.

[12]  P. Ponikowski,et al.  The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study , 2011, European heart journal.

[13]  Akshay S. Desai,et al.  Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. , 2020, European heart journal.

[14]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[15]  P. Ponikowski,et al.  Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.

[16]  Sanjiv J. Shah,et al.  Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. , 2020, JAMA.

[17]  J. Spertus,et al.  Comparison of Patient Self-reported Health Status With Clinician-Assigned New York Heart Association Classification , 2020, JAMA Network Open.

[18]  Gang Chen,et al.  Mapping the Minnesota living with heart failure questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure , 2020, Health and Quality of Life Outcomes.

[19]  C. Thorup,et al.  Prognostic Impact of Self-Reported Health on Clinical Outcomes in Patients with Heart Failure. , 2020, European heart journal. Quality of care & clinical outcomes.

[20]  Center for Devices and Radiological Health , 2020, Definitions.

[21]  C. Torp‐Pedersen,et al.  Quality of life and the associated risk of all-cause mortality in nonischemic heart failure. , 2020, International journal of cardiology.

[22]  D. DeMets,et al.  Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction , 2019, Circulation.

[23]  M. Drazner,et al.  Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. , 2019, Circulation.

[24]  L. Lix,et al.  Impact of missing data on bias and precision when estimating change in patient-reported outcomes from a clinical registry , 2019, Health and Quality of Life Outcomes.

[25]  M. Davidović,et al.  Prognostic value of health-related quality of life in elderly patients hospitalized with heart failure , 2019, Clinical interventions in aging.

[26]  M. Mack,et al.  Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. , 2019, Journal of the American College of Cardiology.

[27]  A. Kfoury,et al.  PROVIDER PERSPECTIVES ON THE FEASIBILITY AND UTILITY OF ROUTINE PATIENT-REPORTED OUTCOMES ASSESSMENT IN HEART FAILURE: A QUALITATIVE ANALYSIS , 2019, Journal of the American College of Cardiology.

[28]  M. Cowie,et al.  Assessing health‐related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach , 2018, ESC heart failure.

[29]  W. Kraus,et al.  Relationship between changing patient‐reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF‐ACTION , 2018, European journal of heart failure.

[30]  E. Novak,et al.  Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes. , 2016, The American journal of cardiology.

[31]  K. Anstrom,et al.  Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. , 2018, Journal of the American College of Cardiology.

[32]  J. Daubert,et al.  Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. , 2018, International journal of cardiology.

[33]  D. Eton,et al.  Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. , 2018, JACC. Heart failure.

[34]  Akshay S. Desai,et al.  Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial , 2018, JAMA cardiology.

[35]  J. Spertus,et al.  Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA cardiology.

[36]  P. Ibrahimi,et al.  Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF , 2017, BMC Cardiovascular Disorders.

[37]  Eiran Z. Gorodeski,et al.  Comparison Between the Kansas City Cardiomyopathy Questionnaire and New York Heart Association in Assessing Functional Capacity and Clinical Outcomes. , 2017, Journal of cardiac failure.

[38]  Akshay S. Desai,et al.  Health-Related Quality of Life Outcomes in PARADIGM-HF , 2017, Circulation. Heart failure.

[39]  P. Ponikowski,et al.  Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials , 2016, European journal of heart failure.

[40]  I. Piña,et al.  Utility of Patient-Reported Outcome Instruments in Heart Failure. , 2016, JACC. Heart failure.

[41]  Gemma Navarro,et al.  The Minnesota living with heart failure questionnaire: comparison of different factor structures , 2016, Health and Quality of Life Outcomes.

[42]  Manuel Gomes,et al.  Addressing Missing Data in Patient‐Reported Outcome Measures (PROMS): Implications for the Use of PROMS for Comparing Provider Performance , 2015, Health economics.

[43]  C. Lam,et al.  Correlation of the New York Heart Association Classification and the 6‐Minute Walk Distance: A Systematic Review , 2015, Clinical cardiology.

[44]  J. Spertus,et al.  Development and Validation of a Short Version of the Kansas City Cardiomyopathy Questionnaire , 2015, Circulation. Cardiovascular quality and outcomes.

[45]  J. Denollet,et al.  Predictors of changes in health status between and within patients 12 months post left ventricular assist device implantation , 2014, European journal of heart failure.

[46]  F. Guillemin,et al.  Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures , 2014, Heart Failure Reviews.

[47]  J. Spertus,et al.  Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[48]  K. Vermeulen,et al.  Preferences of heart failure patients in daily clinical practice: quality of life or longevity? , 2013, European journal of heart failure.

[49]  H. Draper,et al.  Patient-reported outcome alerts: ethical and logistical considerations in clinical trials. , 2013, Journal of the American Medical Association (JAMA).

[50]  D. Goff,et al.  Cardiovascular Health : The Importance of Measuring Patient-Reported Health Status A Scientific Statement From the American Heart Association , 2022 .

[51]  J. Lupón,et al.  Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value , 2013, European journal of heart failure.

[52]  D. J. Veldhuisen,et al.  Quality of life and survival in patients with heart failure , 2013, European journal of heart failure.

[53]  Hanna K. Gaggin,et al.  Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. , 2012, American heart journal.

[54]  M. Pfisterer,et al.  End-of-life preferences of elderly patients with chronic heart failure. , 2012, European heart journal.

[55]  R. McKelvie,et al.  Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial , 2012, Circulation. Heart failure.

[56]  K. Swedberg,et al.  Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. , 2011, European Heart Journal.

[57]  Bradley P Carlin,et al.  Joint Modeling of Multiple Longitudinal Patient-Reported Outcomes and Survival , 2011, Journal of biopharmaceutical statistics.

[58]  S. Reise,et al.  Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger , 2011, Assessment.

[59]  L. Gullestad,et al.  Improved quality of life in Norwegian heart failure patients after follow‐up in outpatient heart failure clinics: results from the Norwegian heart failure registry , 2010, European journal of heart failure.

[60]  J. Iqbal,et al.  Quality of life in patients with chronic heart failure and their carers: a 3‐year follow‐up study assessing hospitalization and mortality , 2010, European journal of heart failure.

[61]  L. Allen,et al.  Critical elements of clinical follow‐up after hospital discharge for heart failure: insights from the EVEREST trial , 2010, European journal of heart failure.

[62]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[63]  Anne L. Taylor,et al.  Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. , 2009, Journal of cardiac failure.

[64]  Karen A. Hartman,et al.  Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. , 2009, Journal of cardiac failure.

[65]  W. Kraus,et al.  Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. , 2009, JAMA.

[66]  Alan Miller,et al.  Does clinician's knowledge of B-type natriuretic peptide levels translate to improvement of quality of life and less hospitalization days in patients with heart failure? , 2009, Progress in cardiovascular nursing.

[67]  J. Denollet,et al.  Health status as a risk factor in cardiovascular disease: a systematic review of current evidence. , 2009, American heart journal.

[68]  M. Rué,et al.  Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses , 2009, Quality of Life Research.

[69]  R. Califf,et al.  Changing preferences for survival after hospitalization with advanced heart failure. , 2008, Journal of the American College of Cardiology.

[70]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[71]  J. Miles,et al.  Development and Validation of a Patient-Centered Health-Related Quality-of-life Measure: The Chronic Heart Failure Assessment Tool , 2008, The Journal of cardiovascular nursing.

[72]  E. Wolfel,et al.  Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). , 2007, Journal of cardiac failure.

[73]  G. Guyatt,et al.  Development and testing of a new measure of health status for clinical trials in heart failure , 1989, Journal of General Internal Medicine.

[74]  Richard Sutton,et al.  Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure , 2006, Heart.

[75]  Derek W Johnston,et al.  Predictors of exercise capacity and everyday activity in older heart failure patients , 2006, European journal of heart failure.

[76]  H. Krumholz,et al.  Health status identifies heart failure outpatients at risk for hospitalization or death. , 2006, Journal of the American College of Cardiology.

[77]  H. Krumholz,et al.  Monitoring clinical changes in patients with heart failure: a comparison of methods. , 2005, American heart journal.

[78]  Craig Ziegler,et al.  Impact of Symptom Prevalence and Symptom Burden on Quality of Life in Patients with Heart Failure , 2005, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[79]  H. Krumholz,et al.  The relationship between B-type natriuretic peptide and health status in patients with heart failure. , 2005, Journal of cardiac failure.

[80]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[81]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[82]  R. Canby,et al.  Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. , 2003, JAMA.

[83]  M. Peberdy,et al.  Relationship between the Minnesota Living With Heart Failure Questionnaire and key ventilatory expired gas measures during exercise testing in patients with heart failure. , 2002, Journal of cardiopulmonary rehabilitation.

[84]  J. Salerno-Uriarte,et al.  [Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[85]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.

[86]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[87]  P. Jones,et al.  The left ventricular dysfunction questionnaire (LVD-36): reliability, validity, and responsiveness , 2000, Heart.

[88]  J. Spertus,et al.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. , 2000, Journal of the American College of Cardiology.

[89]  J. Wilson,et al.  Dissociation between exertional symptoms and circulatory function in patients with heart failure. , 1995, Circulation.

[90]  L. Stevenson,et al.  Quality of life in patients with advanced heart failure. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[91]  A. Jette,et al.  Failure of physicians to recognize functional disability in ambulatory patients. , 1991, Annals of internal medicine.

[92]  K. Swedberg,et al.  Self-assessment of quality of life in severe heart failure. An instrument for clinical use. , 1987, Scandinavian journal of psychology.

[93]  R. Shabetai,et al.  Cardiomyopathy: how far have we come in 25 years, how far yet to go? , 1983, Journal of the American College of Cardiology.